

H K E c a e a d C e a L P e d a d T e S c E c a e H K
L P e d t a e e P P t e c t e t t P a c e e t , a e
e e e t a P a t P a c c a c c e e e a d e e d P c a P a P b P P
a e e a e e a P P P e P c e t e e a
a t t e c t e t t P a c e e t .



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

VOLUNTARY ANNOUNCEMENT
“EXARANE” OBTAINS APPROVAL FROM
NEW ZEALAND

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the
Company, together with its subsidiaries, the **Group**) is pleased to
announce that the Group has obtained approval from the
New Zealand Medicines and Medical Devices
Regulatory Authority (the **Authority**) for the sale of
Exarane in New Zealand.

The **Board** of the Company is pleased to announce that
the Group has obtained approval from the Authority for
the sale of Exarane in New Zealand. The **Board** is
pleased to announce that the Group has obtained approval
from the Authority for the sale of Exarane in New Zealand.

DETAILS OF THE LICENSE

- (I) **Exarane** : E
- (II) **Dosage** : P
- (III) **Strength** : 20 mg/0.2 L, 40 mg/0.4 L, 60 mg/0.6 L, 80 mg/0.8 L, 100 mg/1 L, 120 mg/0.8 L, 150 mg/1 L

BENEFIT AND IMPACT TO THE COMPANY

At the meeting, the board discussed the company's performance in the first half of 2024, the company's business development strategy for the second half of the year, and the company's financial performance. The board also discussed the company's business development strategy for the second half of the year, and the company's financial performance. The board also discussed the company's business development strategy for the second half of the year, and the company's financial performance.

At the meeting, the board discussed the company's performance in the first half of 2024, the company's business development strategy for the second half of the year, and the company's financial performance.

B. B

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li

C a a

, C
28, 2024

A d t e d d e t a c e e t, t e e e c t e d e t t e C a a e M . L M . L T a , M . S a Y a d M . Z a P ; a d t e d e e d e t - e e c t e d e t t e C a a e D . L C a , M . W a P a a d M . Y M .